One Woman's Dream

Page 1

One Woman’s Dream or Another Woman’s Nightmare? The real story behind egg harvesting

Yvonne Valenza

by Michele Clark

Calla Papademas was a 21-year-old Stanford senior with a fashion-model body, above-average grades, and a big heart. She had a boyfriend, planned to go to graduate school, and hoped to make a difference in the world. Enter the fertility industry, the modern dreamweaver of infertile women’s deepest hopes and dreams, an emerging Daddy Warbucks to thousands of young women across the United States who want to get rid of their credit card balance and go to graduate school without being saddled with tens of thousands of debt even before they bring home their first paycheck. Papademas approached an egg donor agency. Following a whirlwind screening process which consisted primarily of questions about the hair color and IQ of her extended family members and in which she was never asked if she had any preexisting health conditions, she was declared a prime candidate for donations. Soon after, Papademas was told that her profile had found a taker who was offering $50,000 dollars for her eggs. After agreeing to be a donor for this couple, she was then informed this couple was no longer available but that another recipient was interested — at a lower price. She moved ahead with the process, despite the lower offer, and received a supply of the drug Lupron, intended to hyperstimulate her ovaries so that multiple eggs could be harvested. On the average, 10 to 15 eggs are harvested at one time, although some harvests can yield more. What was not made clear to Papademas (and what is typically not explained to donors) was that each woman possesses a limited number of eggs, so that with each donation, she decreases her supply and thereby direct-

ly affects her own chances of motherhood in the future. Lupron’s intended purpose is to provide relief to men in the last stages of prostate cancer; Papademas was told that this was an “off-label use” of Lupron. She was also told that the consent forms were standard. In talking about this experience in a deeply moving video interview, she admits that the hurried nature of the selection and consent process were such that “there was not much opportunity to think things through.” She also acknowledges that she felt “chosen” and was grateful for the opportunity to bring other women so much happiness. But it was not meant to be. Papademas had a minuscule tumor on her pituitary gland, a fact never ascertained by the fertility clinic and, within three days of taking Lupron, she found herself in the hospital after suffering a major stroke. After a long recovery period, she is now able to resume her life — after a fashion. She will never be able to bear children and will be on hormone replacement treatment for the rest of her life. And her relationship with the fertility clinic that encouraged her to continue taking the Lupron, even after she called them about increasing migraines and nausea? She was offered a “drop cycle” check for $750 and told that she was no longer a good option. B i g b u s i n e s s — u n r e g u l at e d

Calla Papademas is a victim of a $3-billion-a-year fertility industry driven by the desires of infertile couples.The value of women like Papademas is based on their ability to produce

PRISM 2 0 1 0

31


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.